Geron Corporation

MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy

Retrieved on: 
星期五, 六月 7, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Imetelstat, Telomerase, Patient, Geron Corporation, MAIA, Cancer, Bone marrow, Food, Lung cancer, Syndrome, Pharmaceutical industry

“MAIA is one of the earliest pioneers of telomere targeting as a therapeutic strategy, and we share in the enthusiasm for the FDA approval of imetelstat for rare blood cancers originating in bone marrow.

Key Points: 
  • “MAIA is one of the earliest pioneers of telomere targeting as a therapeutic strategy, and we share in the enthusiasm for the FDA approval of imetelstat for rare blood cancers originating in bone marrow.
  • “Our most recent clinical data shows THIO’s exceptional efficacy in checkpoint inhibitor and chemo-resistant patients in NSCLC.
  • Telomerase is present in over 85% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells.
  • MAIA’s lead candidate is THIO, a telomere targeting agent in clinical development (Phase 2 THIO-101) to evaluate its activity in NSCLC.

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

Retrieved on: 
星期五, 六月 7, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Patient, MDS, Geron Corporation, Risk, Freedom, Corporation, ESA, Anemia, Bone marrow, MD, Food, Cytopenia, Quality of life, Pharmaceutical industry

There is a high unmet need for many LR-MDS patients, particularly those with characteristics having poorer prognosis.

Key Points: 
  • There is a high unmet need for many LR-MDS patients, particularly those with characteristics having poorer prognosis.
  • The intravenous administration of RYTELO every four weeks aligns to routine blood count monitoring for these patients.
  • Clinically relevant adverse reactions in
  • A conference call with Geron management is scheduled at 8am Eastern Time on Friday, June 7, 2024, to discuss the FDA approval and launch of RYTELO.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期四, 五月 16, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Corporation, Employment, Geron Corporation

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 2,910,780 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 2,910,780 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
  • The stock options were granted on May 15, 2024, at an exercise price of $3.90 per share, which is equal to the closing price of Geron common stock on the date of grant.
  • The stock options have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment for the respective employees and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.
  • All of the stock options were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Geron’s 2018 Inducement Award Plan, which was adopted December 14, 2018, and provides for the granting of stock options to new employees.

Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
星期四, 五月 2, 2024
Stem Cells, Biotechnology, FDA, Health, General Health, Pharmaceutical, Oncology, Research, Genetics, Science, Clinical Trials, Corporation, Risk, JAK, Transfusion-dependent anemia, Depreciation, Geron Corporation, Webcast, Exercise, Imetelstat, Ruxolitinib, PDUFA, Patient, EMA, IMPRESS, Marketing, Clinical trial, MDS, Pharmaceutical industry

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business highlights for the first quarter 2024.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business highlights for the first quarter 2024.
  • Revenues for the first quarter of 2024 were $304,000, compared to $21,000 for the same period in 2023.
  • As of March 31, 2024, we had 162 full-time employees, prior to the onboarding of our salesforce in April 2024.
  • ET on Thursday, May 2, 2024, to discuss business updates and first quarter financial results.

Geron to Announce First Quarter 2024 Financial Results on May 2, 2024

Retrieved on: 
星期四, 四月 25, 2024
Biotechnology, Pharmaceutical, Health, Webcast, Geron Corporation, Corporation

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors .

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors .
  • Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m.
  • A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events .
  • An archive of the webcast will be available on the Company’s website for 30 days.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期四, 四月 18, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Geron Corporation, Corporation, Employment

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
  • The stock options were granted on April 17, 2024, at an exercise price of $3.68 per share, which is equal to the closing price of Geron common stock on the date of grant.
  • The stock options have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment for the respective employees and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.
  • All of the stock options were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Geron’s 2018 Inducement Award Plan, which was adopted December 14, 2018, and provides for the granting of stock options to new employees.

Geron to Participate at Upcoming Investor Conferences in April

Retrieved on: 
星期三, 四月 3, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Geron Corporation, Webcast, Corporation, Fireside, Event, Fireside chats

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences:

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences:
    Wednesday, April 10th at 10:15 a.m.
  • ET (Fireside Chat)
    Wednesday, April 17th at 11:30 a.m.
  • ET (Corporate Presentation)
    A webcast of each fireside chat and corporate presentation will be available through the Investor Relations section of the Company’s website under Events .
  • An archive of the webcast will be available on the Company’s website for 30 days.

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
星期二, 三月 19, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical Trials, Montgomery Street, Form, Telephone, Corporation, Sale, Attention, Syndrome, Security (finance), Lexington Avenue, Suite, Form S-3, Prospectus, OrbiMed, Geron Corporation

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock.
  • All of the securities in the offering are to be sold by Geron.
  • The offering is expected to close on or about March 21, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to Geron from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $150.0 million.

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

Retrieved on: 
星期四, 三月 14, 2024
Research, Hospitals, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Bone marrow, Patient, Transfusion-dependent anemia, Corporation, Imetelstat, ODAC, Anemia, Geron Corporation, MDS, Food, Medicine, Pharmaceutical industry

“We are pleased with the Committee’s decision to recognize the positive clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS.

Key Points: 
  • “We are pleased with the Committee’s decision to recognize the positive clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS.
  • Additionally, a sustained increase in mean hemoglobin levels in imetelstat-treated patients was observed over time compared to placebo patients.
  • The ODAC provides the FDA with independent opinions and recommendations from outside medical experts, patients and caregivers, though the recommendations are not binding.
  • Geron plans to commercially launch imetelstat in the U.S. upon potential FDA approval.

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期三, 二月 28, 2024
Biotechnology, General Health, Pharmaceutical, Health, Janus, Hercules, BAT, European Commission, EMA, Marketing, Research, New Drug Application, Anemia, Transfusion-dependent anemia, Syndrome, MAA, MF, FDA, Geron Corporation, Imetelstat, Exercise, PDUFA, Loan, Risk, Primary myelofibrosis, Society, MDS, Civil service commission, JAK, History, European Medicines Agency, Webcast, Register, SVB, Patient, Federal, Clinical trial, Corporation, NDA, Depreciation

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.
  • The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 to the NDA.
  • In September 2023, the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for imetelstat in the same proposed indication as the NDA.
  • Geron will host a conference call at 8:00 am ET on Wednesday, February 28, 2024, to discuss business updates and fourth quarter and full year 2023 financial results.